LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes: Baseline Data From Over 9000 Subjects in the LEADER Trial
View/ Open
Author
Steinberg, William M.
Nauck, Michael A.
Zinman, Bernard
Bergenstal, Richard M.
Mann, Johannes F.E.
Steen Ravn, Lasse
Moses, Alan C.
Stockner, Mette
Baeres, Florian M.M.
Marso, Steven P.
Buse, John B.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1097/MPA.0000000000000229Metadata
Show full item recordCitation
Steinberg, W. M., M. A. Nauck, B. Zinman, G. H. Daniels, R. M. Bergenstal, J. F. Mann, L. Steen Ravn, et al. 2014. “LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes: Baseline Data From Over 9000 Subjects in the LEADER Trial.” Pancreas 43 (8): 1223-1231. doi:10.1097/MPA.0000000000000229. http://dx.doi.org/10.1097/MPA.0000000000000229.Abstract
Objectives: This report from the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial describes baseline lipase and amylase activity in type 2 diabetic subjects without acute pancreatitis symptoms before randomization to the glucagonlike peptide analog liraglutide or placebo. Methods: The LEADER is an international randomized placebo-controlled trial evaluating the cardiovascular safety of liraglutide in 9340 type 2 diabetic patients at high cardiovascular risk. Fasting lipase and amylase activity was assessed at baseline, before receiving liraglutide or placebo, using a commercial assay (Roche) with upper limit of normal values of 63 U/L for lipase and 100 U/L for amylase. Results: Either or both enzymes were above the upper limit of normal in 22.7% of subjects; 16.6% (n = 1540) had an elevated lipase level (including 1.2% >3-fold elevated), and 11.8% (n = 1094) had an elevated amylase level (including 0.2% >3-fold elevated). In multivariable regression models, severely reduced kidney function was associated with the largest effect on increasing activity of both. However, even among subjects with normal kidney function, 12.2% and 7.7% had elevated lipase and amylase levels. Conclusions: In this large study of type 2 diabetic patients, nearly 25% had elevated lipase or amylase levels without symptoms of acute pancreatitis. The clinician must take these data into account when evaluating abdominal symptoms in type 2 diabetic patients.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206347/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:13347586
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)